A couple of corrections for another hit piece:

1) MannKind's tripling of production capacity was mentioned during q3 2014 call on Nov 03, 2014...
Today's PR is about completed validation for an FDA-approved production facility.

2) Havas is as an US-based advertising and public relations company as any with its 98 agencies in the country.
Havas 98 US agencies
Amusing how some try to confuse headquarters location with creativity and local market knowledge...

What death spiral ? AF is blowing smoke into our eyes as usual...

Even if PPS were to set at $1.00 VWAP for 10 consecutive days, total exchanged stock would be $56.9 / (1.00 * 0.9575) = 60 M.
CS outstanding = 410 (Mar 31), thus dilution would be 60 / 410 = 15% ... This no death spiral !
In death spiral the sharks ends owning the company and eating the CS holders.

If PPS were to set at current $4.40 VWAP for 10 consecutive days, total exchanged stock would be $56.9 / (4.40 * 0.9575) = 13 M.
Then dilution would be 13 / 410 = 3% ... This is no death spiral !

As always, AF's agenda primed over reality.

Smart move buying cheap before shorts' smoke disappear and PPS goes up

Afrezza $2.2 M q2 Sanofi revenues in line with scripts data

Expecting good news on EU filing and next products at the q2 call now that the cash situation is clarifying.

Nice POC study at no cost. Could expand in larger SBIR 2...

Only Mannkind's partner Sanofi not afraid of Afrezza as it is the only one offering ultra fast insulin thank to Mannkind.

Having Afrezza on board allows Sanofi to be the only BP selling a complete range of insulins from ultra-fast to long-lasting...

Teva buying Allergan generics great for Antares: Epipen guarantied front row in battle for $1 bil market...

Short interest down another 2.1 M (18 M over last 3 SI), seems the smart shorts saw the ad on the wall...

No doubt the next one will continue the trend as Afrezza is gaining exposure !

Time Mag great targeted exposure: 16.6 M print audience, aged 49, $70k house income.

1.3 M at C$0.74 + 500 at C$0.75 to be precise

yep, someone shaking weak trees for free goodies...

Agreed, a distorting field is active around here:

Anyone researching could confirm the FDA has currently active contracts to access both IMS and Symphony data, awarded Sep 26 and 23, 2014.
This implies both IMS and Symphony data sets are incomplete, as the FDA would only use a single data set if ever one were complete.


Looking at Afrezza Rx data we can see a high discrepancy between IMS and Symphony, both for TRx and NRx:
For example, for 4-days Memorial day week:
Symphony 329 Trx (+2%) 240 NRx (-9%)
IMS 266 Trx (-2%) 175 NRx (-18%)

Nobody knows the true Rx level, we only have access to a lower bound Rx number as reported by IMS or Symphony (meaning the true number is greater).

Speculation of FDA using Symphony not IMS incorrect as FDA accesses both.

The FDA awarded 2 contracts in September 2014 for "Access to Outpatient Prescription and Patient Level Drug Utilization Data":
- IMS for $18.4 M
- Symphony for $16.3 M

Seems only Symphony felt compelled to issue a PR about it...


" It's probably because Symphony has a much more complete source of data than IMS. And that's why the FDA contracts with Symphony. "

Agreed, not all filled scripts are reported: If one ever doubts about that, one just has to compare IMS and Symphony data, and wonder why there is a 20% difference between the two numbers...

Amusing: SA trash article removed coz' material errors of fact...

Bench Brothers Research
Long/short equity, tech, biotech, medium-term horizon
Profile| Send Message| Follow (12 followers)
MannKind's Afrezza: An Expensive Failure
Jul. 14, 2015 2:02 PM ET | 51 comments | About: MannKind Corporation (MNKD), Includes: NVO, PFE, SNY

This article has been removed due to material errors of fact.

patch not yet tested in humans could be Afrezza competitor in barely 4 years ????

Interesting how what Reuters calls a research project could be considered a near term threat to Afrezza by some...


My money is more than ever on Afrezza !

BoA clients thanks all recent cheap shares sellers, covering their 9 M short at $5.55 at no loss.

As I said before, I believe they must have been too close to a loss on these 9 M shares for comfort, as the due date to return them has been approaching fast...

Maybe someone else took over the short position, and is now wondering if it was such a smart move to be sold on it... squeezzzzzze !

Lighting-up the powder: short interest down another 5.3 M...

No doubt the next one will continue the trend as Afrezza is picking up traction.

Positive Afrezza review in Journal of Health-System Pharmacists
The word is spreading across the health care community...

A second-generation inhaled insulin for diabetes mellitus
Grace Ledet, Richard A. Graves, Levon A. Bostanian and Tarun K Mandal

Purpose: The pharmacologic properties of a recently approved inhaled insulin product, its unique delivery system, and the results of clinical safety and efficacy trials are reviewed.

Summary: Afrezza (also called Technosphere Insulin, MannKind Corporation, Valencia, CA) is a novel ultrarapid-acting insulin formulation indicated for use in improving glycemic control in selected patients with type 1 or type 2 diabetes mellitus. Afrezza is not intended as a substitute for traditional basal therapy with injectable long-acting insulin but may be used to provide prandial insulin coverage; it must be used in combination with long-acting insulin in patients with type 1 diabetes. Administered before meals using a dry-powder inhalation device, Afrezza is formulated with a novel excipient (fumaryl diketopiperazine) that dissolves instantly in lung fluid and releases recombinant human insulin for absorption. In clinical trials, rates of hypoglycemia in Afrezza-treated patients were significantly lower than rates reported in comparator groups receiving injectable insulin products. The most commonly reported adverse effect of Afrezza is coughing, which tends to occur shortly after inhalation and is typically mild. Afrezza is not recommended for use in patients who smoke (or have recently stopped smoking) and those with a chronic lung disease such as asthma or chronic obstructive pulmonary disease. Afrezza is not recommended for the treatment of diabetic ketoacidosis.

Conclusion: Afrezza is a safe and effective treatment for selected adults with type 1 or type 2 diabetes, potentially providing an alternative to injectable insulin for prandial blood glucose control.

Interesting: Afrezza way ahead in sales vs analysts forecasts...

Even with flat sales Afrezza would already be beat easily analyst forecasts for both q3 and q4...

This does not account for growing sales trend,
this does not account for starting DTC,
this does not account for improvement in plan placement as we pass the 6 months post launch mark,

Analysts' upgrades are coming....


According to Reuters: Mannkind sales estimates:
analysts average max min
Quarter Ending Sep-15 6 0.52 M 1.80 M 0.00
Quarter Ending Dec-15 6 0.65 M 2.20 M 0.00

According to Symphony:
q2 sales $2.2 M
q3 run-rate based on Jun 26 week= $3.4 M

The house shows fear of losing when it sends employees to breath over your shoulder around the table...

Times have changed since the Las Vegas of old when only the Don could win either legally or by bending the rules (or your fingers .

The casino analogy still works well for the stock market.
I fear some MNKD players got stuck in the past where only they could win without regard of what happened on the table... Time for a reality check for them

Beware: Unsubstantiated (false ?) SEC investigation claims circulating, without any link nor any support on SEC site.

Similar claims already made 2 weeks ago without any link, referring to completely unrelated SEC investigation into microcap/ penny stocks.

Interestingly, the last SEC enforcement in Jan 2014 was about unscrupulous traders doing abusive naked short trading of MNKD...
Gonul Colak and Milen K. Kostov

Symphony TRX 516 (+22%) NRX 386 (+17%) refills 130 (+40%)

Low/ No-copay usual at initiation in diabetes field...

- Farxiga - no-copay
- Invokana - no-copay
- Januvia - $5 max
- Jardiance - no-copay
- Lantus - $25 max
- Levemir - $25 max
- NovoLog - $25 max
- Onglyza - no-copay
- Tanzeum - no-copay
- Toujeo - $15 max
- Tradjenta - $10 max
- Victoza - $25 max

BoA thanks all sellers for the cheap shares, covering its 9 M short at $5.55 at no loss.

Bank of America must have been too close to a loss on these 9 M shares for comfort, as the due date was near...

Agreed, shorts desperation shown in high FUD number.
Shorts have just lost $20 M and still have 120 M shares to cover...

You are very correct in your analysis of the mercenaries at work.

Lots of docs and patients will see them. Nice info on this ADA magazine.
Seems a well targeted great read for diabetics in waiting rooms.

Explains why shorts are getting very nervous...

Afrezza ad example: July/August 2015 Diabetes Forecast issue.
Nice mention $0 copay in this ADA-sponsored magazine.

Afrezza Diabetes Forecast Ad

Thanks to HarryKlari and astronj on IV !

And shorts lost some $20 M on them...

Shorts lost $20M between last 2 SI reports: hear them squeal !

interesting jump in $/ Rx: corresponds to renewals for 3 months and NRx for 2 months.
Seems physicians are getting more comfortable with 3-months initial prescription (using samples as complement)... Nice !

Happenstance? Negative posters on MNKD boards more active both to spread FUD and to dilute any positive thru mindless chat...

Shorts NEED to cover, they read the tea leaves...

30 M short increase between $3.46 and $5.30 in May (Apr 29 -May 27 high-low) that need to be covered, reason enough ?

BankofAmerica's deadline to cover 9M shorts at $5.55 getting closer, reason enough ?

15,000 diabetes clinicians stepped by the Afrezza sign in the exhibit hall, some heard the gospel, some just walked by, all were exposed to Afrezza and will be more receptive.

The real game in diabetes always starts with the ADA...

Great for 3.5-days week, as docs attending ADA ending on Tuesday 09.

When the CEO walk the walk, team dedication becomes natural.

All the more in these times when this is so rare.

Lot's of shorts can't find shares to deliver at settlement, but still continue naked selling...
This is what MNKD being on Reg SHO Threshold means.

How long will MM allow short selling with failure to deliver ?
This is not good for their business if they cannot deliver acquired shares...
Once MM block this, shorts will lose one more tool to artificially mess with the stock.

naked shorting pandemic, high failure to deliver continuing: MNKD 13th day on Reg SHO Threshold list in a row (over 2.1 M fail to deliver per running 5 days)